In vivo targeting of the pre-B-ALL tumours by treatment with CL-BiTE co-injected with CD8+ T cells led to a significant decrease in tumour burden supporting further development as a novel “off-the-shelf” therapeutic for LGR5+ cancer patients with a functional immune system. This evidence concerns the gene LGR5 and cancer.